Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...
Cancers | Free Full-Text | Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic ...
Etiology of Treatment Delays in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer - IOS Press
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
Selecting and Sequencing Therapy in Advanced Urothelial Carcinoma: Navigating a Dynamic Landscape
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cys
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Muscle-invasive and Metastatic Bladder Cancer - INTRODUCTION - Uroweb
1616-Bladder/Urothelial neoad ddMVAC (dd methotrexate vinBLASTine DOXOrubicin ciSplatin) | eviQ
Treatment of metastatic urothelial cancer of the bladder and urinary tract - UpToDate
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial - Clinical Genitourinary Cancer
Neoadjuvant Chemotherapy for Bladder Cancer
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) | BMC Cancer | Full Text
